ACOD1-mediated lysosomal membrane permeabilization contributes to <i>Mycobacterium tuberculosis</i> –induced macrophage death
Abstract
Mycobacterium tuberculosis (Mtb) primarily infects macrophages. In vitro without antibiotics, wild-type Mtb hastens death of the macrophages, but the processes leading to rapid cell death are not well understood. Our earlier work indicated that the death of Mtb-infected mouse macrophages in vitro is markedly exacerbated by induction of interferon-β (IFN-β) [L. Zhang et al., J. Exp. Med. 18 , e20200887 (2021)]. Here, we identified a key downstream response to IFN-β in the context of Mtb infection as the massive induction of cis-aconitate decarboxylase (ACOD1), not only in its canonical subcellular localization in mitochondria but also in the cytosol, where it bound to the lysosome-stabilizing protein HSP70. ACOD1’s product, itaconate, protected Mtb-infected macrophages. However, the contrasting and predominant effect of high-level ACOD1 expression was to act in a noncatalytic manner to promote HSP70’s degradation, leading to lysosomal membrane permeabilization (LMP). Mtb-induced macrophage death was markedly diminished by inhibitors of cysteine proteases, consistent with lysosome-mediated cell death. Neither ACOD1 inhibitors nor cysteine protease inhibitors are suitable for potential host-directed therapy (HDT) of tuberculosis. Instead, this work directs attention to how ACOD1 acts nonenzymatically to promote the degradation of HSP70.
Article Details
Journal Info
Proceedings of the National Academy of Sciences
National Academy of Sciences
Authors (12)
Ziwei Yang
Department of Microbiology and Immunology, Weill Cornell Medicine
Li Zhang
Samantha Ottavi
Division of Chemical Biology and Medicinal Chemistry, University of North Carolina Eshelman School of Pharmacy, University of North Carolina at Chapel Hill
Jacob B. Geri
Merck Center for Catalysis at Princeton University
Andrew Perkowski
Division of Chemical Biology and Medicinal Chemistry, University of North Carolina Eshelman School of Pharmacy, University of North Carolina at Chapel Hill
Xiuju Jiang
Department of Microbiology and Immunology, Weill Cornell Medicine
Daniel Pfau
Department of Microbiology and Immunology, Weill Cornell Medicine
Ruslana Bryk
Jeffrey Aubé
Division of Chemical Biology and Medicinal Chemistry, University of North Carolina Eshelman School of Pharmacy, University of North Carolina at Chapel Hill
Matthew Zimmerman
Center for Discovery and Innovation, Hackensack Meridian Health
Véronique Dartois
Center for Discovery and Innovation, Hackensack Meridian Health
Carl Nathan
Department of Microbiology and Immunology, Weill Cornell Medicine